GlassScriptPhysician profile
Shawn P Brown
NPI 1609910108
$11,578.40
in general payments reported to CMS, 2019-2025
28 companies · $2,228 in 2025
The $2,228 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,199 · 2020: $777 · 2021: $1,679 · 2022: $1,489 · 2023: $1,751 · 2024: $2,455 · 2025: $2,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,434.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,379.99 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $1,377.49 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $1,260.43 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $1,173.91 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $1,142.52 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $760.64 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $650.90 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $502.18 | 2021-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $442.02 | 2019-2025 | Lybalvi |
| Neurocrine Biosciences, INC. | $371.08 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $267.96 | 2019-2025 | Abilify Asimtufii |
| Allergan, INC. | $264.34 | 2019-2020 | |
| Biogen, INC. | $208.39 | 2024-2025 | Zurzuvae |
| Bausch Health US, LLC | $125.38 | 2020-2021 | |
| Indivior INC. | $117.80 | 2022-2024 | Perseris |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $108.11 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.27 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $56.59 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $56.29 | 2022-2023 | Jornay Pm |
| Neuronetics, INC. | $47.98 | 2019-2025 | Neurostar Tms Therapy System |
| Eisai INC. | $42.30 | 2021 | |
| Bioxcel Therapeutics, INC. | $41.48 | 2023 | Igalmi |
| Sage Therapeutics, LLC | $31.73 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $29.40 | 2025 | |
| Almatica Pharma LLC | $19.77 | 2024 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $14.15 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $12.74 | 2019 | |
| Noven Therapeutics, LLC | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.